GLP-1 agonists blunt migraine-like pain in mice, in both sexes
- Repeated nitroglycerin dosing was used to induce a chronic migraine-like state in male and female mice, and three GLP-1 receptor agonists (liraglutide, semaglutide, dulaglutide) were tested as prophylaxis against the reference drug propranolol.
- All three reduced mechanical, cold and orofacial pain responses dose-dependently in both sexes, with efficacy similar to propranolol and no change in the metabolic readouts, whereas propranolol caused a male-specific metabolic effect.
- For semaglutide, pharmacological blockade and brainstem/trigeminal ganglion mRNA analysis pointed to sex-dependent involvement of opioid and endocannabinoid pathways.
💡 Points Based on the abstract
Three drugs of one class working equally well is a nicer signal than any single compound, and including females is the right call for a pain model. But the nitroglycerin paradigm is a hypersensitivity readout, not a migraine attack, and the mouse doses aren't mapped to human exposure. Before I'd believe it, I'd want to know how much is central GLP-1R action and how much is just weight or glycaemic change in a model this noisy.